Verve Therapeutics (VERV) Trial Halt Case

The plaintiff has voluntarily dismissed the case, ending the lawsuit.

D. Massachusetts

Court

1:24-cv-12218

Case number

08/09/2022

Class period Start

04/01/2024

Class period End

10/28/2024

Lead Plaintiff motion deadline

$VERV stockholders filed a claim against Verve for misleading them about the Heart-1 trial halt and overstating the benefits of their LNP delivery system.
After the news on April 2, 2024, $VERV dropped by over 34%.
Verve investors can join this case to be notified about potential recovery.

Case Details:

On November 7, 2022, Verve announced that the FDA placed a hold on the company's Investigational New Drug application, halting a potential clinical trial for VERVE-101 to treat patients with heterozygous familial hypercholesterolemia.

Then, on April 2, 2024, Verve Therapeutics announced that the Heart-1 trial would be stopped.

The halt was due to a problem with the LNP delivery system after a patient received 0.45 mg/kg of VERVE-101.

On this news, $VERV fell by 34.9% on April 2, 2024.

Based on these events, $VERV investors filed a claim against Verve, accusing the company of the following:

Verve failed to fully disclose why the Heart-1 trial was halted.
They also overstated the benefits of their LNP delivery system.

Considering all the representations, investors suspect Verve misled them about why the Heart-1 trial was halted and exaggerated the benefits of their LNP delivery system.

Case Status

Voluntary Dismissed

Alleged Offence

Misleading Statements,

Failure to Disclose,

Negligence,

Breach of Fiduciary duty,

Omissions

Suspected Party

Directors,

Management,

Government Authority,

Service Provider

Security Type

Stocks

Trade Direction

Long

Shock Event Date

11/07/2022

Filing date

08/27/2024

Lead Plaintiff Deadline

10/28/2024